The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1656
August 8, 2022
View Complete Issue         Table of Contents 2019 
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
August 8, 2022 (Issue: 1656)
The FDA has approved oteseconazole (Vivjoa – Mycovia), a new oral azole antifungal, to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC. Oteseconazole is the first drug to be approved in the US...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
Article code: 1656e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.